• +918149924059
  • sales@factviewresearch.com

Global Cytomegalovirus Infection Market Size, Share & Trends Analysis Report By End-user, By Region, and Segment Forecasts, 2023 - 2032
  • Published Date: Nov, 2023
  • |
  • Pages: 200
  • |
  • Industry:
  • |
  • Format: PDF
  • |
  • Share:

  • Report Summary
  • Table of Contents
  • Segmentation
  • Methodology
  • Download Sample

Cytomegalovirus infection is a common herpesvirus infection that can manifest with a range of symptoms, from asymptomatic cases to fever, fatigue, and severe symptoms affecting internal organs such as the eyes and brain. CMV is a contagious illness transmitted through bodily fluids, including blood, semen, saliva, urine, and breast milk. The primary treatment method typically involves antiviral medications, which are effective in slowing down the replication of the virus but do not completely inhibit it. Commercially available antiviral drugs like Ganciclovir, Foscarnet, Valganciclovir, Cidofovir, and others are commonly used for cytomegalovirus treatment.

Global Cytomegalovirus Infection Market was valued at US $550.2 Mn in 2022 and is expected to reach US $995 Mn by 2032, growing at a CAGR of 6.1% during the forecast period 2023-2032.

Cytomegalovirus treatment accounts for approximately 0.8% of the total revenue in the global infectious disease diagnostics market. The increasing prevalence of viral infections and growing awareness of cytomegalovirus symptoms are anticipated to drive the demand for cytomegalovirus treatment worldwide. However, it's important to note that the cytomegalovirus treatment market is susceptible to fluctuations influenced by macroeconomic factors and industry standards, particularly in light of strict regulations governing biopharmaceutical development, production, and licensing.

The market has witnessed a decrease in its Business Performance Score (BPS) values due to the limited effectiveness of the therapy in patients with severe immunosuppression or disseminated disease. The global COVID-19 pandemic has led to a rise in such cases, further underscoring the limitations of cytomegalovirus treatment and resulting in a decline in BPS values, negatively impacting market growth.

Conversely, the market has a more positive outlook in recent times. This shift is primarily attributed to the FDA's approval of the first drug designed for adults and paediatric patients with cytomegalovirus infections and diseases that cannot be effectively managed with currently available antiviral treatment methods in 2022. This development has opened up opportunities for market growth in the upcoming years.

COVID-19 Impact on Cytomegalovirus Infection Market

The cytomegalovirus treatment market was significantly affected by the COVID-19 pandemic. Patients with cytomegalovirus infection had a higher susceptibility to COVID-19 compared to those without the infection, which impacted the demand for treatment during the pandemic. An article published in the Journal of Medical Virology in October 2021 indicated that patients with cytomegalovirus infection tended to experience more severe COVID-19 symptoms upon hospital admission than individuals without such infections. This increased risk associated with cytomegalovirus infection is expected to have a noteworthy influence on market growth in the foreseeable future.

However, as the number of COVID-19 cases decreases in the post-pandemic period, it is anticipated that the market will experience growth. This growth can be attributed to the growing emphasis on the development of advanced treatments for cytomegalovirus, which will contribute to market expansion in the coming years.

Factors Driving the Cytomegalovirus Infection Market


Introduction of new drug therapies

Introducing new drug therapies significantly drives the Cytomegalovirus (CMV) treatment market. This driver encompasses developing and approving novel medications specifically designed to target CMV infections. Here's an explanation of how this driver contributes to the CMV treatment market.

Novel drug therapies often exhibit heightened effectiveness in the management of CMV infections. These medications are meticulously designed to more efficiently hinder the replication and dissemination of the CMV virus within the body. Consequently, they hold the potential to yield improved clinical outcomes for patients, leading to the mitigation of both the severity and duration of symptoms associated with CMV infections. When juxtaposed with older treatment modalities, innovative drug therapies are meticulously engineered to possess a more favourable side-effect profile. This translates into patients undergoing treatment with a diminished risk of encountering adverse effects, ultimately enhancing their overall quality of life during therapy. As CMV has the propensity to develop resistance against existing antiviral drugs over time, novel drug therapies frequently tackle this challenge by employing distinct mechanisms of action. This strategic approach diminishes the likelihood of the virus evolving resistance, thus extending the period of treatment effectiveness for individuals afflicted with CMV.

The advent of fresh drug therapies can broaden the spectrum of patients who can benefit from CMV treatment. This expansion encompasses diverse demographics such as paediatric patients, individuals burdened with specific comorbidities, or those exhibiting varying degrees of immunosuppression. Consequently, this diversification augments the market's reach and the potential pool of patients who may benefit from these therapies.

New therapies offer a ray of hope for cases where CMV infections exhibit inadequate response to currently available treatments. These novel treatment modalities provide an alternative option for managing the formidable challenges of resistant or refractory CMV infections. Introducing cutting-edge CMV treatments can invigorate market growth by attracting investments from pharmaceutical enterprises and intensifying competition within the industry landscape. This catalyzes innovation and advances in CMV research, ultimately leading to further progress in the field.


Lack of awareness related to CMV infection

The absence of awareness concerning CMV (Cytomegalovirus) infection poses a significant hurdle in CMV treatment. This obstacle is characterized by a deficiency in comprehension, awareness, and acknowledgement among the general populace, healthcare practitioners, and even certain medical experts regarding CMV infection. Due to this lack of awareness, CMV infections frequently evade or receive diagnosis at later stages. This delay in identification can culminate in a more severe disease manifestation and the onset of complications, as prompt intervention plays a pivotal role in managing CMV.

Regular screening for CMV remains uncommon, especially within low-risk populations. The absence of awareness regarding the prevalence of CMV and its associated potential hazards means that many individuals, including pregnant women and immunocompromised patients, may forgo vital screenings. CMV symptoms can closely resemble those of other viral infections, engendering the possibility of misdiagnosis or confounding among healthcare practitioners. This, in turn, may lead to unsuitable treatment or management approaches, potentially exacerbating the patient's condition.

Expectant mothers may not receive adequate information regarding the perils of CMV infection during pregnancy, encompassing the prospect of fatal transmission. This deficit in awareness can translate into missed opportunities for preventive measures and early detection. Within immunocompromised patients, healthcare practitioners may not be sufficiently vigilant in monitoring for CMV reactivation, a prevalent complication. This oversight stemming from a lack of awareness may result in delayed identification and treatment within this vulnerable demographic. In summary, insufficient awareness regarding CMV infection represents a considerable challenge in CMV treatment. This dearth of knowledge impedes timely diagnosis, appropriate preventive measures, and effective disease management, underscoring the necessity of heightened awareness campaigns and education initiatives to address this issue comprehensively.


Development of Targeted Therapies

The development of targeted therapies is a significant trend in the cytomegalovirus (CMV) infection market. This trend involves creating medications specifically designed to combat CMV infections by focusing on unique aspects of the virus's biology. Targeted therapies are meticulously crafted to identify precise components or mechanisms within the CMV virus essential for its replication and survival. This precision empowers these therapies to intervene in the virus's life cycle with remarkable accuracy. Targeted therapies frequently demonstrate superior effectiveness when juxtaposed with broad-spectrum antiviral drugs in managing CMV infections. By directly impeding crucial viral processes, these therapies can efficiently curtail viral replication and exert control over the infection. As targeted therapies are centred on specific viral elements, they may offer a more favourable side-effect profile than older, less focused treatments. This translates to potentially reducing adverse effects for patients undergoing targeted therapy, ultimately enhancing their overall quality of life during treatment. CMV possesses the capacity to develop resistance to antiviral drugs over time. Targeted therapies can mitigate this risk by employing distinct mechanisms to combat the virus, thereby diminishing the likelihood of viral resistance development. This extension of the period during which CMV treatment remains effective is of paramount significance.

Cytomegalovirus Infection Market Segmentation 

By Service

The segmentation analysis of the Cytomegalovirus Infection Market focuses specifically on electronics design and engineering, assembly, manufacturing, logistics services, etc. Segmenting the EMS market in this manner allows both EMS providers and clients to identify specific areas of expertise and services that cater to their needs. Industry trends, technological advancements, and evolving customer demands within the electronics manufacturing landscape influence the growth of each segment.

Within these segments, the engineering services category is experiencing a more substantial growth rate during the projected period. This is primarily attributed to increased research and development activities by Electronic Assembly Manufacturers. This segment encompasses services related to the design and development of electronic products. EMS providers collaborate with clients to create product concepts design printed circuit boards (PCBs), mechanical components, and embedded software.

By Diagnosis

Segmenting the market based on diagnosis allows healthcare providers to employ various methods for detecting and managing CMV infections. Serologic tests help in understanding an individual's immune response to the virus, while PCR tests and other diagnostic tools offer more direct and precise means of identifying the presence of the virus, determining the stage of infection, and monitoring treatment efficacy. This comprehensive approach enables more accurate diagnosis and appropriate management of CMV infections. Serologic tests are blood tests used to detect antibodies produced by the body in response to a CMV infection. These tests determine whether a person has been exposed to the virus in the past or is currently infected.

They can indicate the stage of infection (such as recent or past exposure) and are helpful in assessing the immune response to the virus. PCR tests detect the genetic material of the CMV virus in bodily fluids like blood, urine, or saliva. This highly sensitive test amplifies and identifies specific segments of the virus's DNA, providing a more direct means of diagnosing an active CMV infection. PCR tests are particularly useful in diagnosing acute infections and monitoring the effectiveness of treatment.Others segment could include additional diagnostic methods, such as antigen detection tests, viral cultures, or newer, innovative diagnostic technologies being developed for CMV detection and monitoring.

By Diseases

Segmenting the market based on diseases allows healthcare providers to understand and address the specific clinical challenges presented by CMV infection. It helps in tailoring treatments, monitoring, and management strategies according to the affected organ systems or clinical conditions, optimizing care and outcomes for individuals dealing with CMV-related complications. CMV retinitis is a common manifestation in individuals with weakened immune systems, particularly those with HIV/AIDS. It affects the eyes, leading to inflammation of the retina and potential vision loss if left untreated. CMV pneumonia can occur in immunocompromised individuals, causing respiratory issues and pneumonia-like symptoms. It's a significant concern for those with weakened immune systems, such as transplant recipients or people with HIV/AIDS.

CMV can cause ulcers in the digestive tract, particularly in the esophagus or intestines. These ulcers might lead to various gastrointestinal symptoms and complications, especially in individuals with compromised immune systems. CMV encephalitis is a rare but severe condition involving inflammation of the brain, which can lead to neurological symptoms, cognitive impairment, and potentially life-threatening consequences.Others category might encompass additional manifestations of CMV infection, such as hepatitis, mononucleosis-like symptoms, or other less common but significant health issues associated with the virus.

By Drug

Segmenting the market based on drugs is essential for healthcare providers to offer a range of treatment options, each with its specific characteristics and considerations. Different medications may be used based on the severity of the infection, the affected organ systems, the patient's health status, and potential drug resistance. This segmentation ensures that appropriate medications can be selected to optimize the management and treatment of CMV infections. Cidofovir is an antiviral medication used to treat CMV retinitis in individuals with weakened immune systems, such as those with HIV/AIDS. It works by interfering with the replication of the virus. Foscarnet is another antiviral drug used to treat CMV infections, especially when the virus is resistant to other treatments. It's often utilized in cases where Ganciclovir or Valganciclovir may not be effective.

Valganciclovir is an oral prodrug of Ganciclovir and is used to treat various CMV infections, including retinitis and other systemic manifestations, particularly in transplant recipients and individuals with HIV/AIDS. Ganciclovir is an antiviral medication available in various forms (intravenous, oral, or ophthalmic gel) used for treating CMV infections, particularly CMV retinitis and other systemic manifestations in immunocompromised individuals.Other category might encompass additional antiviral medications, immunomodulatory drugs, or emerging treatments being researched or used in specific cases of CMV infection.

By Route of Adminisitration

Segmentation in the cytomegalovirus (CMV) infection market based on administration routes categorizes the different ways medications and treatments are delivered for managing the condition. Oral treatments for CMV involve medications taken by mouth in the form of tablets, capsules, or liquid formulations. Some antiviral medications used to manage CMV, such as Valganciclovir, are available in oral forms. These are convenient for individuals to administer at home, especially for long-term treatment or prophylaxis. Parenteral treatments are administered through routes other than the digestive tract, typically via injections, infusions, or intravenous methods.

Some antiviral medications for CMV, like Cidofovir or Ganciclovir, are administered intravenously in hospital or clinical settings. This route is often used for more severe cases, immediate treatment needs, or in individuals who may have difficulties with oral medications. Others segment might include alternative or specialized administration methods not classified under oral or parenteral routes. It could encompass newer drug delivery systems, investigational routes, or emerging treatment options that might be under research or development for CMV infection.

By Application

The segmentation analysis of stem cell transplantation, organ transplantation and congenital CMV infection.

The Stem Cell Transplantation segment is projected to command a significant market share during the forecast period. Stem cell transplantation is well-positioned to benefit from incorporating new cell types, opening up substantial opportunities for companies to strengthen their foothold in the market. Consequently, there has been a remarkable increase in companies developing cell therapies in recent years. Key growth drivers for this market segment are expected to include increased funding from government and private organizations to support clinical trials for stem cell therapy, effective manufacturing guidelines for stem cell therapy products, and the established efficacy of these products.

According to a study published by Springer in July 2021, CMV cell-mediated immunity assays have the potential to be utilized as supplementary tests for creating personalized treatment plans by identifying patients who experience immune reconstitution. Promising new therapies for addressing CMV infections include Maribavir and adoptive T-cell therapy. Additionally, there are ongoing CMV vaccine trials for prevention. Consequently, this segment will experience robust growth throughout the forecast period.

Furthermore, the market is expected to receive a boost from various regulatory authorities' increasing number of product approvals. For instance, in September 2022, Health Canada granted authorization (Notice of Compliance) for Takeda's LIVTENCITY (maribavir) for the treatment of adults with post-transplant cytomegalovirus (CMV) infection/disease who are refractory (with or without genotypic resistance) to one or more prior antiviral therapies. This authorization extends to individuals who have undergone either a solid organ transplant or a hematopoietic stem cell transplant.

By End Users

In the cytomegalovirus (CMV) infection market, segmentation based on end users categorizes where individuals receive treatments, care, and support for managing the condition. Hospitals play a significant role in treating severe cases of CMV infection, especially those affecting multiple organ systems or causing life-threatening complications. Hospital settings provide comprehensive medical care, inpatient treatment, access to specialized equipment, and round-the-clock monitoring for individuals with critical CMV-related conditions like CMV pneumonia or encephalitis. Specialized clinics dedicated to infectious diseases or virology often cater to individuals with CMV infections. These clinics offer more focused care, expertise, and specific treatment regimens for managing CMV, particularly in cases such as CMV retinitis or gastrointestinal ulcers caused by the virus.

Home-based care allows individuals with CMV infection to receive treatment, monitoring, and supportive care in the comfort of their homes. This might involve the administration of oral medications, specialized care instructions, and periodic check-ins by healthcare professionals to manage the condition outside of a clinical or hospital setting.Others segment may include non-traditional healthcare settings, such as research institutions conducting clinical trials or studies related to CMV, community health centers offering support and information, or non-profit organizations providing resources and advocacy for individuals affected by CMV infection.

By Distribution Channel

In the market for cytomegalovirus (CMV) infection, the segmentation based on distribution channels categorizes where individuals can access medications and treatments for managing the condition. Hospital pharmacies, located within healthcare facilities, play a crucial role in providing medications and specialized care for inpatients and outpatients dealing with CMV infections. These pharmacies dispense medications prescribed by healthcare providers, ensuring patients have access to necessary treatments during their hospital stays or visits. Retail pharmacies, commonly found in community settings such as drugstores or standalone outlets, provide medications and prescriptions for various health conditions, including CMV infections.

They offer accessible points for individuals to fill their prescriptions, obtain refills, and receive guidance on managing the condition. With the advent of digital healthcare services, online pharmacies provide a convenient means for individuals to access medications for CMV infections. These platforms allow patients to order medications online and have them delivered to their homes, providing remote access to necessary treatments. Others category might encompass specialty or compound pharmacies offering personalized formulations or specific medication preparations for managing CMV infections. It might also include non-profit organizations providing support, resources, and advocacy for individuals affected by CMV infection.

By Regions

By region, the market is divided into North America, Europe, APAC, and Others. Others are further divided into the Middle East and South America.

North America is anticipated to maintain a substantial global market share throughout the forecast period. Several factors, including the increasing occurrence of cytomegalovirus (CMV) infections, growing consumer awareness, and prominent market players, are expected to influence market expansion in this region.

For example, an article released by NINDS in July 2022 reported that CMV infects approximately 50% to 80% of adults by age 40 and stands as one of the most common congenital infections in the United States each year. Similarly, data from CMV Canada, published in June 2021, indicated that one out of every 200 Canadian infants contracts CMV during pregnancy. The report further highlighted that one in five cases of congenital CMV resulted in a lasting disability, such as hearing impairment or developmental delays. Conversely, a BMC article published in September 2022 noted that the seroprevalence of CMV infection in pregnant Mexican women in 2021 was notably higher among those aged 30 to 39 (86.5%) than those under 20. This heightened incidence of CMV within the North American population is expected to fuel the demand for effective treatment, thereby propelling market growth.

Furthermore, the increasing number of product approvals aimed at providing safe and efficacious treatments to patients is poised to drive market expansion during the forecast period. For instance, in November 2021, Takeda Pharmaceuticals obtained FDA approval for Maribavir, a product designed to treat post-transplant cytomegalovirus infection/disease in adults and pediatric patients aged 12 years or older that is refractory to treatment.

In light of these factors, which include the escalating prevalence of CMV infections, the presence of influential market players, and frequent advancements in product development, it is anticipated that the market in North America will experience substantial growth in the foreseeable future.

Cytomegalovirus Infection Market Competitive Landscape

The competitive landscape of the cytomegalovirus market involves assessing the competitive landscape to understand the strengths, weaknesses, opportunities, and threats. Cytomegalovirus treatment providers are investing in the research development of innovative and more effective treatments for CMV infections. Some of the major players in the global cytomegalovirus infection treatment and diagnosis market are Merck & Co. Inc., Cell Medical Ltd., Chimerix, Inc., Affymetrix, Inc., Abbott Laboratories, Inc., Becton, Dickinson and Company, Johnson & Johnson, Bio-Rad Laboratories, Inc., and F. Hoffmann-La Roche Ltd.

Recent Developments 

  • In September 2022, ProBioGen and the City of Hope entered a commercial license agreement to utilize the AGE1.CR.pIX vaccine manufacturing platform to produce the Cytomegalovirus (CMV) vaccine.
  • In June 2022, Synklino successfully concluded a Series A fundraising round, securing the funding of EUR 29.8 million (USD 31.8 million). The company specializes in developing medications for treating chronic viral infections, with the funding earmarked for advancing its drug candidate, SYN002, designed for combating cytomegalovirus (CMV).
  • In November 2021, Takeda Pharmaceutical Company Limited announced the approval by the U.S. Food and Drug Administration (FDA) of LIVTENCITY (maribavir) for the treatment of post-transplant cytomegalovirus (CMV) infection in adults and pediatric patients, that is unresponsive to treatment with ganciclovir, cidofovir, valganciclovir, or foscarnet. LIVTENCITY, classified as a new molecular entity, targets CMV through its action on pUL97, inhibiting viral DNA replication, nuclear egress, and encapsidation. 

Table of Contents

  1. Executive summary
    • MARKET Definitions
  3. research methodology
  4. market outlook
    • Key Trends
    • COVID- 19 IMPACT ON GLOBAL Cytomegalovirus Infection Market
      • Drivers
        • Introduction of New Drug Therapies
        • High Prevalence of Infectious Diseases
        • Upsurge in Patient Pool of CMV Retinitis
      • Restraints
        • Adverse effects and risks related to cytomegalovirus drugs
      • Opportunities
        • Growth in investments in combination therapies
        • Development of Point-of-Care Diagnostics
      • Challenges
        • Antiviral drug safety
        • Limited treatment options
        • Lack of awareness related to CMV infection
      • PriCing Analysis
        • Threat of new entrants
        • Threat of substitute
        • Bargaining power of suppliers
        • Bargaining power of buyers
        • Intensity of competitive rivalry
  1. GLOBAL Cytomegalovirus Infection Market, By Diagnosis, MARKET ESTIMATION AND FORECAST, 2019-2032), value (USD million)
    • Serologic Test
    • Polymerase Chain Reaction (PCR) Test
    • Others
  2. GLOBAL Cytomegalovirus Infection Market, BY diseases, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
    • Retinitis
    • Pneumonia
    • Gastrointestinal Ulcers
    • Encephalitis
    • OTHERS
  3. GLOBAL Cytomegalovirus Infection Market, BY Drug, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
    • Cidofovir
    • Foscarnet
    • Valganciclovir
    • Ganciclovir
    • OTHERS
  4. GLOBAL Cytomegalovirus Infection Market, BY route of administration, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
    • oral
    • parenteral
    • OTHERS
  5. GLOBAL Cytomegalovirus Infection Market, BY application, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
    • Stem Cell Transplantation
    • Organ Transplantation
    • Congenital CMV Infection
    • other
  6. GLOBAL Cytomegalovirus Infection Market, BY end-users, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
    • hospitals
    • speciality clinics
    • homecare
    • others
  7. GLOBAL Cytomegalovirus Infection Market, BY distribution channel, MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
    • Hospital Pharmacy
    • Retail Pharmacy
    • Online Pharmacy
    • Others
  8. GLOBAL Cytomegalovirus Infection Market, REGIONAL ANALYSIS MARKET ESTIMATION AND FORECAST, 2019-2032, value (USD million)
    • NORTH AMERICA Cytomegalovirus Infection Market
      • North America Cytomegalovirus Infection Market, By Country
        • US
        • Canada
        • Mexico
      • North America Cytomegalovirus Infection Market, By Diagnosis
      • North America Cytomegalovirus Infection Market, By Diseases
      • North America Cytomegalovirus Infection Market, By Drug
      • North America Cytomegalovirus Infection Market, By Route of Administration
      • North America Cytomegalovirus Infection Market, By Application
      • North America Cytomegalovirus Infection Market, By End-Users
      • North America Cytomegalovirus Infection Market, By Distribution Channel
    • EUROPE Cytomegalovirus Infection Market
      • Europe Cytomegalovirus Infection Market, By Country
        • Germany
        • UK
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
      • Europe Cytomegalovirus Infection Market, By Diagnosis
      • Europe Cytomegalovirus Infection Market, By Diseases
      • Europe Cytomegalovirus Infection Market, By Drug
      • Europe Cytomegalovirus Infection Market, By Route of Administration
      • Europe Cytomegalovirus Infection Market, By Application
      • Europe Cytomegalovirus Infection Market, By End-Users
      • Europe Cytomegalovirus Infection Market, By Distribution Channel
    • ASIA PACIFIC Cytomegalovirus Infection Market
      • Asia Pacific Cytomegalovirus Infection Market, By Country
        • China
        • Japan
        • India
        • Australia
        • Singapore
        • South Korea
        • Thailand
        • Indonesia
        • Malaysia
        • Philippines
        • Rest of Asia Pacific
      • Asia Pacific Cytomegalovirus Infection Market, By Diagnosis
      • Asia Pacific Cytomegalovirus Infection Market, By Diseases
      • Asia Pacific Cytomegalovirus Infection Market, By Drug
      • Asia Pacific Cytomegalovirus Infection Market, By Route of Administration
      • Asia Pacific Cytomegalovirus Infection Market, By Application
      • Asia Pacific Cytomegalovirus Infection Market, By End-Users
      • Asia Pacific Cytomegalovirus Infection Market, By Distribution Channel
    • MIDDLE EAST & AFRICA Cytomegalovirus Infection Market
      • Middle East & Africa Cytomegalovirus Infection Market, By Country
        • UAE
        • Saudi Arabia
        • South Africa
        • Rest of Middle East & Africa
      • Middle East & Africa Cytomegalovirus Infection Market, By Diagnosis
      • Middle East & Africa Cytomegalovirus Infection Market, By Diseases
      • Middle East & Africa Cytomegalovirus Infection Market, By Drug
      • Middle East & Africa Cytomegalovirus Infection Market, By Route of Administration
      • Middle East & Africa Cytomegalovirus Infection Market, By Application
      • Middle East & Africa Cytomegalovirus Infection Market, By End-Users
      • Middle East & Africa Cytomegalovirus Infection Market, By Distribution Channel
    • SOUTH AMERICA Cytomegalovirus Infection Market
      • South America Cytomegalovirus Infection Market, By Country
        • Brazil
        • Argentina
        • Peru
        • Rest of South America
      • South America Cytomegalovirus Infection Market, By Diagnosis
      • South America Cytomegalovirus Infection Market, By Diseases
      • South America Cytomegalovirus Infection Market, By Drug
      • South America Cytomegalovirus Infection Market, By Route of Administration
      • South America Cytomegalovirus Infection Market, By Application
      • South America Cytomegalovirus Infection Market, By End-Users
      • South America Cytomegalovirus Infection Market, By Distribution Channel
  1. GLOBAL Cytomegalovirus Infection Market, COMPETITIVE Intelligence
    • competitor benchmarking
    • competitive quadrant
    • market share analysis, 2022 (%)
  2. GLOBAL Cytomegalovirus Infection Market, COMPANY ANALYSIS
    • Abbott
      • Company Overview
        • Business outlook
        • Headquarter
        • Established/Incorporated
        • Headcounts/ Employee strength
      • Financial Overview
        • Sales/revenue
        • R&D expenditure
        • Business segment sales share
        • Regional sales share
      • Product Offerings
      • SWOT Analysis
      • Key Developments (Expansion/New Product Development/Agreement/Mergers & Acquisitions, Partnership/Investment/Etc.)
    • Astellas Pharma Inc.
    • AstraZeneca
    • Aurobindo Pharma
    • BD
    • Bio-Rad Laboratories, Inc.
    • Cipla Inc.
    • Endo International plc
    • Hoffmann-La Roche Ltd.
    • GlaxoSmithKline plc
    • Glenmark Pharmaceuticals Limited
    • Johnson & Johnson Private Limited
    • Lupin
    • Merck & Co., Inc.
    • Mylan N.V.
    • Novartis AG
    • Pfizer Inc.
    • Sanofi
    • Teva Pharmaceutical Industries Ltd.
    • Zydus Cadila
    • OTHERS


*Financials and Details May Not be Included in Case of Privately Held Company

Global Cytomegalovirus Infection Market Segmentation

Cytomegalovirus Infection by Type: Market Size & Forecast 2023-2030

  • Diagnostics
  • Therapeutics

Cytomegalovirus Infection by Application: Market Size & Forecast 2023-2030

  • Congenital CMV Infection
  • Transplant-Associated CMV Infection
  • CMV Retinitis
  • CMV Gastritis
  • CMV Pneumonitis

Cytomegalovirus Infection by End User: Market Size & Forecast 2023-2030

  • Hospitals
  • Clinics
  • Blood Banks
  • Organ Transplant Centers

Cytomegalovirus Infection by Distribution Channel: Market Size & Forecast 2023-2030

  • Direct Sales
  • Tendering Process
  • Online Sales

Cytomegalovirus Infection by Geography: Market Size & Forecast 2023-2030

  • North America (USA, Canada, Mexico)
  • Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
  • Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
  • South America (Brazil, Argentina, Columbia, Rest of South America)
  • Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)

Major Players:

  • Merck & Co., Inc.
  • Hoffmann-La Roche Ltd.
  • GlaxoSmithKline plc
  • Pfizer Inc.
  • Novartis AG
  • Sanofi S.A.
  • Johnson & Johnson
  • Abbott Laboratories
  • Astellas Pharma Inc.
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Gilead Sciences, Inc.
  • Chimerix, Inc.
  • Vical Incorporated
  • Quidel Corporation
  • Thermo Fisher Scientific Inc.
  • Luminex Corporation
  • Cepheid
  • DiaSorin S.p.A.
  • Bio-Rad Laboratories, Inc.
  • Quidel Corporation
  • Hologic, Inc.
  • Danaher Corporation
  • Siemens Healthineers AG

Frequently Asked Questions

Get Your Customized Report